About Cardinor
Cardinor is a company based in Oslo (Norway) founded in 2015. Cardinor has raised $921.84 thousand across 5 funding rounds from investors including European Union, IIG PLC and EIC Fund. The company has 2 employees as of December 31, 2019. Cardinor offers products and services including Secretoneurin ELISA Assay. Cardinor operates in a competitive market with competitors including Topera, CoreMap, Wearlinq, Smartheart and Bionet, among others.
- Headquarter Oslo, Norway
- Employees 2 as on 31 Dec, 2019
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Cardinor As
-
Annual Revenue
$359.64 K (USD)8as on Dec 31, 2021
-
Net Profit
$592.42 K (USD)598as on Dec 31, 2021
-
EBITDA
$592.63 K (USD)598as on Dec 31, 2021
-
Total Equity Funding
$921.84 K (USD)
in 5 rounds
-
Latest Funding Round
$171.84 K (USD), Seed
Mar 31, 2021
-
Investors
European Union
& 2 more
-
Employee Count
2
as on Dec 31, 2019
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cardinor
Cardinor offers a comprehensive portfolio of products and services, including Secretoneurin ELISA Assay.
Assay for measuring secretoneurin in heart failure patients
Funding Insights of Cardinor
Cardinor has successfully raised a total of $921.84K across 5 strategic funding rounds. The most recent funding activity was a Seed round of $171.84 thousand completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cardinor
Cardinor has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, IIG PLC and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are directed by IIG toward life sciences startups.
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Cardinor
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cardinor
Investment portfolio details for Cardinor
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cardinor
Detailed financials for Cardinor
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cardinor Comparisons
Peer comparison for Cardinor
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cardinor
Cardinor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Topera, CoreMap, Wearlinq, Smartheart and Bionet, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Catheter-based electrophysiology mapping for atrial fibrillation treatment is offered.
|
|
| Locked | Locked | Locked |
Atrial fibrillation detection platform is provided for heart disorder management.
|
|
| Locked | Locked | Locked |
A wearable ECG device is provided for heart disorder detection.
|
|
| Locked | Locked | Locked |
Portable EKG device for home-based cardiac monitoring and early detection of issues.
|
|
| Locked | Locked | Locked |
Cord blood banking service provider along with services on genetic testing
|
Detailed competitors of Cardinor
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cardinor
Complete news archive for Cardinor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cardinor
Cardinor was founded in 2015.
Cardinor is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
Cardinor is a funded company, having raised a total of $921.84K across 5 funding rounds to date.
As of Dec 31, 2019, the latest employee count at Cardinor is 2.
Annual revenue of Cardinor is $359.64K as on Dec 31, 2021.
Cardinor was founded in 2015 in Oslo, Norway, as a provider of biomarker-based assays targeting cardiovascular diseases. The assays utilize the neuropeptide secretoneurin, linked to cardiomyocyte calcium handling, to support identification of therapeutic strategies for heart disease patients. Operations focus on diagnostic applications, with the initial emphasis placed on arrhythmia testing within the biotechnology sector.
Cardinor offers Secretoneurin ELISA Assay.
Cardinor has 3 investors. Key investors include European Union, IIG PLC, and EIC Fund.